Brattle Principal Pinar Bagci has authored the United Kingdom
chapter of Global Competition Review's (GCR) 2017
edition of the Handbook of Competition Economics. The handbook
identifies the primary issues that antitrust economists are
tackling today and provides contact details for competition
agencies' economists in 79 jurisdictions around the world.
In her chapter on the UK, Dr. Bagci provides an overview of the
Competition and Markets Authority's (CMA) two significant
investigations concluded in the past year in the country's
energy and retail banking markets, which examined concerns over
lack of fair competition and pricing in the respective market
Dr. Bagci highlights that the key finding of both CMA
investigations relates to consumer behavior, and the apparent
reluctance to research and switch energy providers or retail banks
due to the belief that small to moderate financial gain is an
insufficient reason to switch. She suggests that while the question
of financial gain in switching in the CMA investigations is
significant, the investigations were perhaps overly simplistic by
purely reflecting pricing and failing to include factors such as
reputation, trust, and innovation, all of which are also highly
relevant in consumers' decisions to switch providers.
To read the chapter in its entirety, please visit the
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
To print this article, all you need is to be registered on Mondaq.com.
Click to Login as an existing user or Register so you can print this article.
The CAT in the UK heard on 17 January 2017 an application by Flynn Pharma Ltd and Flynn Pharma (Holdings) Ltd to suspend the Competition and Markets Authority's direction to reduce the price of an epilepsy drug.
A recent case found that a private equity firm was liable for its portfolio company's antitrust violations. This client alert explains that private equity firms, when selecting potential investments...
The Competition and Markets Authority (CMA) has issued fines totalling Ł44.99 million to a number of pharmaceuticals companies for engaging in anti-competitive conduct and agreements in relation to the supply of paroxetine.
Online travel agencies which greatly helped maintain occupancy rates during the difficult years in the 1990s have been accused of exploiting their position of strength in a manner that contravenes the rules of fair competition.
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).